Embolic medical devices

Information

  • Patent Grant
  • 9713475
  • Patent Number
    9,713,475
  • Date Filed
    Friday, April 18, 2014
    10 years ago
  • Date Issued
    Tuesday, July 25, 2017
    6 years ago
Abstract
An occlusive device for occluding a target area can include an elongate member having opposing first and second side edges extending longitudinally along the member and a member width. The member can have a collapsed configuration in which the first and second side edges are curled toward each other about a longitudinal axis of the member. Further the member can have an expanded configuration in which the member form a series of loops and the first and second side edges uncurl to be spaced apart from each other.
Description
BACKGROUND

Field of the Inventions


The present disclosures relate to implantable devices. More specifically, the present disclosures relate to occlusive devices that can be implanted endovascularly, and in some embodiments, for aneurysm therapy.


Description of the Related Art


Numerous embolization devices have been provided for aneurysm treatment. Generally, braid-ball embolic devices, coils, and other types of embolization operate through blood flow disruption and subsequent thrombus formation. Currently, aneurysms are treated with embolic coils, such as Covidien Axium™ or Stryker GDC® 10. These embolic devices are small coils with outside diameters ranging from 0.0090 inches to 0.0145 inches. The devices are heat treated on mandrels to impart a two or three-dimensional shape that are favorable for aneurysm geometries.


SUMMARY

At least one aspect of the disclosure provides methods and apparatuses for delivering an occluding device or devices (e.g., stent or stents) in the body. The occluding device can easily conform to the shape of the tortuous vessels of the vasculature. The occluding device can be used in a variety of applications. For example, in some embodiments, the occluding device can direct the blood flow within a vessel away from an aneurysm by substantially or fully blocking a neck of the aneurysm or substantially or fully disrupting blood flow within an aneurysm. Further, embodiments of the occluding devices disclosed herein provide numerous advantages in a single device that were only available previously by using a combination of different medical devices.


In accordance with some embodiments, a device is disclosed that can have a flattened profile and formed from either a tubular material or a flat sheet. The device can be heat treated to impart a two or three-dimensional shape.


The device can be made from polymers, metals or a combination of polymers and metals. The device can be braided, knitted or woven with multiple filaments within a single stitch or carrier. Radiopaque filaments can be added to enhance visibility during and after delivery to target vasculature. Embodiments of the device can have a wider profile than a coil and therefore, compared to coils, require fewer devices to obtain adequate aneurysm neck coverage and aneurysm sac stasis. The device can also provide superior framing support of the aneurysm sac.


In accordance with some embodiments, a method of delivering one or more devices comprises forming the device into a cylindrical or “spiral” shape and delivering it through a catheter. Forming the device into a cylindrical or spiral shape can minimize the crossing profile and allow access to distal anatomy. Thus, some embodiments can be used in vasculature that is smaller than that possible for traditional stents or other such expandable structures. Further, the pushing resistance of the device can be decreased, thereby improving the pushability of the device.


The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses or embodiments (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination with each other or one or more other independent clauses, to form an independent clause. The other clauses can be presented in a similar manner. The following is a non-limiting summary of some embodiments presented herein:


Clause 1. An occlusive device for occluding a target area, comprising: an elongate member having opposing first and second side edges extending longitudinally along the member and a member width, the member having (i) a collapsed configuration in which the first and second side edges are curled toward each other about a longitudinal axis of the member, and (ii) an expanded configuration in which the member form a series of loops and the first and second side edges uncurl to be spaced apart from each other.


Clause 2. The device of Clause 1, wherein the first and second side edges uncurl to be spaced apart from each other at no more than twice the member width.


Clause 3. The device of Clause 2, wherein the first and second side edges uncurl to be spaced apart from each other at approximately the member width.


Clause 4. The device of any one of the preceding clauses, wherein the elongate member comprises a shape memory material.


Clause 5. The device of Clause 4, wherein the elongate member comprises a material that is in austenite state when in the expanded configuration.


Clause 6. The device of any one of the preceding clauses, wherein the elongate member comprises a flattened tubular member.


Clause 7. The device of any one of the preceding clauses, wherein the member comprises a plurality of filaments.


Clause 8. The device of Clause 7, wherein a spacing of the filaments varies along the length of the member.


Clause 9. The device of Clause 7, wherein the plurality of filaments are braided together.


Clause 10. The device of Clause 7, wherein the plurality of filaments are woven together.


Clause 11. The device of Clause 7, wherein the member is configured such that the filaments form a flat tubular member.


Clause 12. The device of Clause 11, wherein the filaments of the tubular member have a variable pitch.


Clause 13. The device of any one of the preceding clauses, wherein the elongate member comprises at least one slit.


Clause 14. The device of Clause 13, wherein the at least one slit extends along the longitudinal axis of the member.


Clause 15. The device of Clause 13, wherein the elongate member comprises a plurality of slits extending along the longitudinal axis of the member and spaced apart in a substantially linear configuration.


Clause 16. The device of any one of the preceding clauses, wherein the first and second side edges comprise a plurality of wing elements extending laterally therefrom.


Clause 17. The device of Clause 16, wherein the wing elements extend from opposing sides of the elongate member.


Clause 18. The device of Clause 17, wherein a pair of wing elements extend from opposing sides at a first longitudinal position along the member.


Clause 19. The device of Clause 17, wherein the wing elements comprise first and second sets of wing elements, the first set extending from a first side of the member and the second set extending from a second side of the member at different longitudinal positions than the first set.


Clause 20. An occlusive device for occluding a target area, comprising: a elongate member comprising a plurality of filaments, the member having a central backbone and a plurality of wing elements extending from the backbone, the member having (i) a collapsed configuration in which the wings are curled toward the backbone about a longitudinal axis of the member, and (ii) an expanded configuration in which the backbone forms a series of loops.


Clause 21. The device of Clause 20, wherein the wing elements extend from opposing sides of the elongate member.


Clause 22. The device of any one of Clauses 20-21, wherein the wing elements comprise first and second sets of wing elements, the first set extending from a first side of the member and the second set extending from a second side of the member at different longitudinal positions than the first set.


Clause 23. The device of any one of Clauses 20-22, wherein the elongate member comprises a flat, braided tubular member.


Clause 24. The device of any one of Clauses 20-23, wherein the wings uncurl away from the backbone in the expanded configuration.


Clause 25. A method of operating an occlusive device assembly, comprising: advancing an elongate member in a collapsed configuration within a catheter, the member having opposing first and second side edges extending longitudinally along the member, the first and second side edges being curled toward each other about a longitudinal axis of the member in the collapsed configuration; and urging a distal end of the member beyond the catheter distal end to release the member to an expanded configuration in which the first and second side edges move away from each other and the member curls into a series of loops.


Clause 26. The method of Clause 25, further comprising positioning the catheter distal end at an ostium of an aneurysm, wherein the urging comprises urging the member into a fundus of the aneurysm.


Additional features and advantages of the subject technology will be set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and embodiments hereof as well as the appended drawings.


It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are included to provide further understanding of the subject technology and are incorporated in and constitute a part of this specification, illustrate aspects of the disclosure and together with the description serve to explain the principles of the subject technology.



FIG. 1 is a side cross-sectional view illustrating deployment of a device into an aneurysm, according to some embodiments.



FIG. 2A is a perspective view of an occlusive device that can be released into a target area of a body lumen, according to some embodiments.



FIG. 2B is a perspective, cross-sectional view of the device along its longitudinal axis, wherein the device is in a first, expanded configuration that can be achieved upon expansion within the target area, according to some embodiments.



FIG. 2C is a perspective, cross-sectional view of the device along its longitudinal axis, wherein the device is in a second, collapsed configuration that can be maintained during advancement to the target area, according to some embodiments.



FIGS. 3A-3I illustrate aspects and optional features that can be incorporated into the device, according to some embodiments.



FIG. 4 illustrates a device in a collapsed configuration within a catheter, according to some embodiments.



FIGS. 5A-6B illustrate cross-sectional views of a device disposed within a catheter, according to some embodiments.



FIGS. 7A-7F illustrate progressive steps in the deployment of a device into an aneurysm, according to some embodiments.



FIG. 8 illustrates coverage of a neck of an aneurysm using one or more devices, according to some embodiments.



FIGS. 9A-9B illustrate additional shapes of a device in an expanded configuration, according to some embodiments.





DETAILED DESCRIPTION

In the following detailed description, numerous specific details are set forth to provide a full understanding of the subject technology. It should be understood that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and techniques have not been shown in detail so as not to obscure the subject technology.


Further, while the present description sets forth specific details of various embodiments, it will be appreciated that the description is illustrative only and should not be construed in any way as limiting. Additionally, it is contemplated that although particular embodiments of the present inventions may be disclosed or shown in the context of aneurysm therapy, such embodiments can be used in other occlusive therapies within the vasculature. Furthermore, various applications of such embodiments and modifications thereto, which may occur to those who are skilled in the art, are also encompassed by the general concepts described herein.


In accordance with an aspect of some embodiments disclosed herein, occlusive devices and methods of use are provided that provide advantages over, for example, the use of a traditional coil, a stent, or a braided structure, whether alone or in combination, in occluding an aneurysm. Some embodiments can provide a greater aneurysm surface contact than traditional coils, which can allow less device material to be deployed while tending to increase the surface area of the implanted occlusive device, which can result in increased thrombogenicity. Likelihood of aneurysm recanalization can be greatly reduced through some embodiments, which can provide excellent wall apposition and neck coverage. Further, some embodiments can also be easier to manipulate within the aneurysm dome or cavity. For example, the device can more easily conform to the interior shape of the aneurysm cavity. Furthermore, when an aneurysm begins to reduce in size, aspects of some embodiments allow the device to be deformable such that the device can be compressed or collapse in size to promote healing of the aneurysm, which may not generally possible using traditional coils or other devices.


For example, FIG. 1 is a side cross-sectional view illustrating deployment of a device into an aneurysm, according to some embodiments. As shown, a device 10 can be advanced to a target aneurysm 40 using a device assembly 20. The device 10 can be advanced from a catheter 22 of the assembly 20 and through a neck 42 of the aneurysm 40 toward a fundus 44 of the aneurysm 40.


The device 10 can comprise a body 12, which can have an elongate shape. In some embodiments, the body 12 can be disposed in a first configuration when positioned within the catheter 22 and expand to a second configuration when released from the catheter 22 into the aneurysm 40. For example, in some embodiments, the first configuration can be achieved when the body 12 is constrained within the catheter 22 and curled or rolled primarily in a direction transverse to a longitudinal axis of the body 12. In some embodiments, the second configuration can be achieved when the body 12 is released from the catheter 22 and curled or rolled primarily in a direction along the longitudinal axis of the body 12. Thus, as the body 12 of the device 10 is released from the catheter 22, a primary curl or roll of the device 10 can transition from one direction along the longitudinal axis to the other, such that the device morphs from an elongate, substantially tubular configuration to a bundled, rounded shape within the aneurysm 40. As the device 10 is released, the body 12 can contact incrementally more of the aneurysm wall and cover more of the neck 42 of the aneurysm 40 until the neck 42 is substantially covered or blocked. Eventually, whether a single or multiple devices are inserted into the aneurysm 40, the wall of the aneurysm can be more completely contacted by device(s) and the volume of the aneurysm 40 can be substantially packed or filled such that circulation or fluid movement is slowed or stopped within the aneurysm 40 and in to the aneurysm 40 through the neck 42 is substantially slowed or stopped.



FIG. 2A depicts an embodiment of an occlusive device 100 that can be released into a target area of a body for occluding the target area. The target area can be a body lumen or space, such as aneurysms, including neurovascular or intracranial aneurysms, blood vessels, or other hollow anatomical structures. According to some embodiments, the device 100 can provide numerous and distinct advantages over other occlusive devices, such as coils and expandable filamentary structures, including stents, wire cages, and other known occlusive devices.


For example, in the case of aneurysm therapy, the device 100 can pack or fill a target volume, and accommodate the shape of the target volume, functions which stent or braided structures may not adequately perform on their own. Further, the device 100 can contact an irregular sidewall shape of the aneurysm. Furthermore, the device 100 can also maximize coverage of the aneurysm neck, adequately grip the sidewall of the aneurysm to prevent device herniation or slippage, promote a healing response along the aneurysm neck, provide predictable expansion to a desired expanded shape, and achieve these ends without requiring other framing or neck blocking devices, functions which coil structures may not adequately perform on their own.


Referring to FIG. 3A, The device 100 is illustrated as comprising a body, ribbon, or elongate member 150 formed from a braid having a number of strands, such as metallic wires or polymeric filaments. For example, the body 150 can comprise nitinol or other suitable (superelatic)? materials. For example, in accordance with some embodiments, the material of which the body 150 is constructed can permit the body 150 to be substantially straight (and relatively elongated, for example, in the second configuration for delivery) while at or near room temperature and coiled (and relatively shortened or looped, for example, in the first configuration for space packing or filling in the target area) while at or near human body temperature. However, in some embodiments, the device 100 can also comprise other types of materials or configurations of material. For example, the device 100 can comprise a bioresorbable material or polymer. Further, the material can also comprise cobalt chromium.


Further, the device 100 can comprise a woven, knit, braided, or a non-braided, non-knit, and non-woven, single, continuous piece of material, or molded pieces, whether in a flat sheet or tubular configuration. The device 100 can comprise a single or multi-layer sheet or tubular structure. In some embodiments, the device 100 can comprise a laser-cut or photo-etched material. The device 100 can also comprise a material formed from one or more non-woven fibers, e.g., long fibers, which are pressed or otherwise bonded together into a tubular or flat sheet configuration.


In some embodiments, the device 100 can be configured as a tubular structure, which can be flattened to provide a generally flat cross-sectional profile. The flattening of the tubular structure can thus provide a multi-layer sheet or structure whose layers are, incidentally, connected along the lateral longitudinal edges of the device.


In some embodiments, the device 100 can comprise a flat sheet, which can be folded onto itself one or more times along the longitudinal axis of the device 100. The folding of the material can thus provide a multi-layer sheet or structure. The use of such a sheet of material can provide ease of manufacturing and enable greater control of the ends of the device 100.


In some embodiments, regardless of the material or configuration of the device 100, the device 100 can comprise a body that has a textured surface or a smooth surface. For example, in some embodiments, the device can comprise a body that has an irregular, porous, dimpled, braided, woven, or knitted surface. Thus, some embodiments of the device 100 can be configured to provide pores, apertures, indentations, or interstitial spaces that impart a desired level of thrombogenicity and/or resistance to blood flow. Further, such pores, apertures, indentations, or interstitial spaces can advantageously engage the sidewall of the aneurysm while being released into the aneurysm. As such, during deployment of the device 100, a textured surface can tend to enhance wall apposition and ensure that the device 100 engages with the aneurysm wall and does not move within or herniate from the aneurysm.


Further, instead of or in addition to such a textured surface, thrombogenic materials can be employed as coatings, additives or otherwise in the device 100, for example gold, platinum, platinum-iridium alloy, or fibrin. Where a braid is employed, the braid wire metals may be selected to maximize the electrical currents (and any resulting thrombogenicity).


In use, the device 100 shown in FIG. 2A can be loaded into a delivery system, such as a catheter, and delivered to a target area within the body. According to some embodiments, when released from the delivery system in the target area, the device 100 can assume an expanded, first, or primary configuration 110, as shown in FIGS. 2A-2B. However, when the device 100 is being delivered to the target area, can also have a collapsed, second, or secondary configuration 120, such as that shown in the embodiment in FIG. 2C. Thus, to facilitate delivery of the device 100, the body 150 can be positioned in a configuration such as the collapsed configuration 120 when in a delivery catheter. Upon being released from the delivery catheter, the body 150 can preferentially assume the expanded configuration 110. Accordingly, when unconstrained, the body 150 may tend to self-adjust or move to the expanded configuration 110 (as opposed to staying in or moving to the collapsed configuration 120).


In the expanded configuration 110 shown in FIGS. 2A-2B, a body 150 of the device 100 can be looped, curved, curled, or rolled about an axis that is transverse to a longitudinal axis 160 of the body 150. Further, in the collapsed configuration 120 shown in FIG. 2C (e.g., achieved when the device 100 is in a catheter), a body 150 of the device 100 can be looped, curved, curled, or rolled about an axis that is aligned with a longitudinal axis 160 of the body 150.


In some embodiments, the body 150 can comprise a “curl vector” 162 that can be geometrically defined, using the “right-hand rule,” as the resulting vector or direction in which the thumb points when the fingers of the hand are curled along the same arc or orientation of the body 150. As shown in FIG. 2B, when in the expanded configuration 110, the curl vector 162 can be oriented substantially transverse relative to the longitudinal axis 160 of the body. In some embodiments, the curl vector 162 can extend in a generally perpendicular direction relative to the longitudinal axis 160 when the body 150 is in the expanded configuration 110.


For example, the body 150 can comprise opposing first and second side edges 172, 174. In the expanded configuration 110, at a given point along the longitudinal axis 160, the first and second side edges 172, 174 can be spaced apart at a first distance. Additionally, as shown FIG. 2B, the device 100 can comprise a leading edge 176 (which can represent a cross-section of the device that is substantially perpendicular to the longitudinal axis 160), which can have a substantially flat cross-sectional shape when the device 100 is in the expanded configuration 110.


The device 100 can substantially pack or fill the internal volume of the body lumen, such as an aneurysm, after being released from a delivery system. For example, as discussed further below, when the device 100 is in the expanded configuration 110, the device 100 can comprise a variety of three-dimensional shapes, including spherical or non-spherical shapes, including, hemispheres, noodles, coils, prolate spheroids, oblate spheroids, bowls, non-spherical surfaces of revolution (e.g., toruses, cones, cylinders, or other shapes rotated about a center point or coplanar axis), and/or combinations thereof. For example, FIG. 2A illustrates an embodiment of the device having a ball-shaped or substantially spherical configuration while FIGS. 9A-9B illustrate embodiments of a device 100 having a semi-cylindrical, 3-D, or cylindrical configurations.


However, in the collapsed configuration 120, illustrated in FIG. 2C, the body 150 can have a substantially cylindrical configuration. For example, the body 150 can be curved, curled, or rolled around or about a line substantially parallel relative to the longitudinal axis 160. As shown in FIG. 2C, when in the collapsed configuration 120, the body 150 can be curled such that the curl vector 162 can be oriented substantially parallel relative to the longitudinal axis 160 of the body. When the body 150 is in the collapsed configuration 120, even though the curl vector 162 may not be substantially parallel relative to the longitudinal axis 160, the curl vector 162 can be within about 30°, within about 20°, or within about 10° of parallel relative to the longitudinal axis 160. Further, in the collapsed configuration 120, the first and second side edges 172, 174 can be curled toward each other.


For example, as noted above, in the expanded configuration 110, at a given point along the longitudinal axis 160, the first and second side edges 172, 174 can be spaced apart at the first distance. When moved to the collapsed configuration 120, at a given point along the longitudinal axis 160, the first and second side edges 172, 174 can be spaced apart at a second distance, which is less than the first distance. Additionally, as shown FIG. 2C, the leading edge 176 of the device 100 (which can represent a cross-section of the device that is substantially perpendicular to the longitudinal axis 160) can have a curved shape or cross-section when the device 100 is in the collapsed configuration 110.


In some embodiments, the first and second side edges 172, 174 can be substantially parallel relative to each other in the collapsed configuration 120. For example, the first and second side edges 172, 174 can extend substantially parallel relative to the longitudinal axis 160. In some embodiments, the first and second side edges 172, 174 can also extend at least partially helically about the longitudinal axis 160 in the collapsed configuration 120.


During delivery of the device 100, although curled or rolled about the longitudinal axis 160 in the collapsed configuration 120, the first and second side edges 172, 174 may slightly deflect, bend, or curve onto the longitudinal axis 160 while passing through tortuousities of the vasculature. For purposes of this disclosure, such motion is considered typical during advancement of the device 100 to the target area and when device 100 is positioned in the collapsed, second configuration 120 within the catheter, the device 100 is considered to be in the collapsed configuration 120 regardless of the degree or amount of curving or looping of the device 100 onto the longitudinal axis 160.


Advantageously then, some embodiments can provide a device that is sufficiently flexible to bend or deflect while advancing through tortuosities of the vasculature without kinking or breaking fibers or filaments of the device. Further, some embodiments also allow the device 100 to be subjected to substantial pushing forces without collapsing or buckling. For example, some embodiments allow the device to be positioned in a generally tubular or rolled shape, thus advantageously increasing the strength of the device when under axial compression in the collapsed configuration.


As noted above, in accordance with some embodiments, the body 150 of the device 100 can be configured to have at least one preset configurations. For example, the body 150 of the device 100 can be biased such that the device 100 assumes a first preset two or three-dimensional configuration in the expanded configuration 110. However, in some embodiments, the body 150 of the device 100 can also comprise a second preset configuration in which the device 100 assumes the collapsed configuration 120.


In some embodiments, the body 150 of the device 100 can be biased toward one or both of the first or second preset configurations. The device 100 can also be preset to assume the first configuration as a primary configuration and to assume the second configuration is a secondary configuration. For example, the body 150 of the device 100 can have dual stable positions. Optionally, the first configuration can be preferred when no external forces are being exerted upon the body 150.


Further, some embodiments can be provided in which the device has only one or both of these preset configurations. For example, in some embodiments, although the body 150 of the device 100 may have only a preset expanded configuration 110, the device 100 can be rolled or curled sufficiently to permit loading and advancement of the device 100 within a catheter. Further, in some embodiments, although the body 150 of the device 100 may have only a preset collapsed configuration 120, the device 100 can incorporate another structure, such as the tensioning member discussed below, to impart a two or three-dimensional shape to the device 100.



FIGS. 3A-3I show top views of various embodiments of an occlusive device in a planar or flat configuration, for purposes of illustration. Any of the devices illustrated in FIGS. 3A-3I can be formed using a tubular mesh material that is flattened into a two-layer sheet. However, any of the devices illustrated in FIGS. 3A-3I can also be configured as a single layer sheet of mesh material, which can be folded once, twice, or more times, or not at all in forming the device. Cross-sectional profiles of some embodiments are illustrated in FIGS. 5A-6B. Further, in accordance with some embodiments, the device, whether formed from a flattened tubular mesh or a single layer sheet (folded or not), can optionally comprise one or more features, such as slits or protrusions that can facilitate access through the device or increase the coverage of the device in its expanded configuration. Other features can also be optionally incorporated into the device to provide radiopacity to the device, a drug delivery means, swellable materials, or other features such as those disclosed herein or known in the art.


For example, FIG. 3A illustrates a section of the device 100 in which the body 150 is configured such that the first and second edges 172, 174 are substantially straight or extend substantially parallel relative to the longitudinal axis 160 of the device 100.



FIG. 3B illustrates that the device 100 can optionally comprise at least one longitudinal slit. As shown, the device 100 can comprise at least one slit 190 extending along the longitudinal axis 160 of the device 100. In some embodiments, the device 100 can comprise a plurality of slits 190, such as that shown in FIG. 3B. The slit 190 can permit the clinician to advance or inject another embolic device, such as one or more coils or an embolic material or liquid, into the aneurysm. For example, a suitable liquid embolic is the Onyx™ liquid embolic system manufactured by Covidien LP, Irvine, Calif. Onyx™ liquid embolic system is a non-adhesive liquid used in the treatment of brain arteriovenous malformations. Onyx™ liquid embolic system is comprised of an ethylene vinyl alcohol (“EVOH”) copolymer dissolved in dimethyl sulfoxide (“DMSO”), and suspended micronized tantalum powder to provide contrast for visualization under fluoroscopy. Other liquid embolic solutions are also envisioned.



FIG. 3C illustrates that in some embodiments, the device 100 can optionally comprise a shape-imparting, structural, or tensioning member 194. The body 150 can be formed separately from the tensioning member 194 such that the tensioning member 194 acts as a separate, independent component that influences the shape of the body 150. As shown in FIG. 3C, the tensioning member 194 can be interwoven into the braid.


The tensioning member 194 can be coupled to one or more sections of the device 100 in order to provide stretch resistant or anti-stretch properties to the device 100. Thus, in some embodiments, although the device 100 can be formed from a resilient or deformable material, the incorporation of the tensioning member 194 can ensure that the length of the device 100 varies only slightly or is substantially unchanged during advancement of the device 100 through the delivery system and during expansion of the device 100 within the target area. Further, in some embodiments, the tensioning member 194 can resiliently provide stretch resistance. Thus, the length of the device 100 can increase and the tensioning member 194 can resist the stretching and urge the device 100 toward its unstretched, original length.


In some embodiments, the tensioning member 194 may not only provide anti-stretch capabilities, but can also impart a two or three-dimensional configuration to the device 100 when in the expanded configuration 110. The tensioning member 194 may be employed to impart any of the two or three-dimensional configurations discussed herein, or other suitable such configurations.


A desired unconstrained configuration can be heat-set or otherwise processed into the tensioning member 194. The tensioning member 194 can be employed with a device 100 which itself has no particular heat-set or otherwise preset unconstrained configuration, or with a device 100 which does have a preset two or three-dimensional configuration. Where only the tensioning member 194 has a preset unconstrained configuration, the tensioning member 194 can urge the device 100 into a two or three-dimensional unconstrained or semi-constrained configuration upon release from a delivery catheter or into the target area. The unconstrained configuration thus achieved by the device 100 can be generally similar to the unconstrained configuration that is preset in the tensioning member 194.


The tensioning member 194 can comprise first and second ends, with at least one of the ends being coupled to the body 150 of the device 100. In some embodiments, the tensioning member 194 can comprise first and second ends that are each coupled to respective first and second portions of the device 100. The first and second portions of the device 100 can comprise first and second end portions.


The tensioning member 194 can facilitate delivery of the device 100 by providing either a pulling or pushing function during advancement of the device 100. For example, in some embodiments, the tensioning member 194 can be coupled at one end to only one portion or end of the device 100. In such embodiments, the other end of the tensioning member 194 can be grasped or coupled to a portion of the delivery system for providing anti-stretch properties. As such, the device 100 can be delivered within a catheter using a core wire or assembly that comprises a pad or engagement member at its distal end. The engagement member of the core wire can engage the device 100 at a point distal to a proximal end of the device 100. In some embodiments, the engagement member can engage the device 100 at a point proximal to the distal end of the device 100, such as at a midpoint along the longitudinal axis of the device 100, or between the midpoint and the distal end of the device 100. The tensioning member 194 can be coupled to the proximal end of the device 100 and extend distally such that a distal end of the tensioning member 194 is engaged with a portion of the core wire, such as the engagement member. In some embodiments, the distal end of the tensioning member 194 can be frictionally engaged between the engagement member and the device 100 or otherwise releasably engaged with the core wire. Further, in some embodiments, the tensioning member 194 can be attached to a distal end of the core wire or engagement member and a proximal end of the device 100 and be configured to dissolve upon release of the device 100 within the target area.


Alternatively, in accordance with some embodiments, the tensioning member 194 can provide column strength to the device 100. Thus, the tensioning member 194 may be used to urge the device 100 distally through the catheter during delivery of the device 100 by manually pushing a proximally extending portion of the tensioning member 194 in a distal direction. For example, the tensioning member 194 can be coupled to a distal end portion of the body 150 of the device 100 and a proximal end of the tensioning member 194 can be contacted (and some embodiments, along with a proximal end of the body 150) to push the device 100 distally through a catheter lumen. As such, some embodiments of the delivery system can be configured to abut or the coupled to a proximal end of the tensioning member 194 for pushing the device 100 through the catheter.


In addition, similar to the body 150 of the device 100, the tensioning member 194, which can be formed separately from the body 150, may comprise one or more nitinol wires, which can be pre-shaped as discussed above. For example, nitinol or AUSTENITIC nitinol (or other material) can be employed, which is substantially straight (and relatively elongated) while at or near room temperature and coiled (and relatively shortened) while at or near human body temperature. Such a tensioning member can be used as discussed above to maintain an axial length of the device 100 during delivery through a catheter lumen, but permit or facilitate movement from the collapsed configuration 120 to the expanded configuration 110. Further, as noted above, some embodiments can be provided in which the tensioning member 194 imparts a two or three-dimensional shape to the device 100 upon release from the catheter.


Referring now to FIGS. 3D-3E, the body 150 of the device 100 can be configured such that the edges 172, 174 converge or diverge relative to each other. For example, as shown in FIG. 3D, the body 150 can comprise one or more enlarged portions, which can comprise wings, bulges, that extend laterally outward from the longitudinal axis 160 of the body 150.



FIG. 3D illustrates a plurality of enlarged portions 200 that extend generally symmetrically from opposing sides of the device 100. Further, FIG. 3E illustrates another embodiment of the device 100 in which enlarged portions 200 extend in a staggered configuration from opposing sides of the device 100. Furthermore, FIG. 3G illustrates another embodiment in which the enlarged portions 200 have different widths or sizes.


The shape and dimensions of the enlarged portions 200 can, as illustrated, provide the enlarged portions 200 with a rounded, semicircular edge. However, the enlarged portions or wings 200 can also be configured such that the edges 172, 174 have a sinusoidal shape. The enlarged portions can comprise any shape, size, or occupy any position along the length of the device, and any combinations thereof.


The enlarged portions 200 can be formed from a single, continuous piece of material with the body 150. The body 150 can be cut or otherwise shaped to include the enlarged portions 200. For example, the body 150 can be formed from a braided sheet or tube whose filaments are stretched laterally and heat-set to form the enlarged portions 200. However, in some embodiments, the enlarged portions 200 can be formed separately from and subsequently coupled to the body 150.


Further, the enlarged portions 200 can be configured to roll or curl about the longitudinal axis 160 or to laterally self-expand from a compressed configuration. The embodiments illustrated in FIGS. 3D-3E illustrate rollable or curlable enlarged portions 200. Further, FIGS. 3F-3G illustrate embodiments of the device 100 in which the enlarged portions 200 are in respective compressed and expanded positions 210, 212. When compressed or prior to contact with the fluid or heat, the enlarged portions 200 can cause the pic count (i.e., the count of the per-inch-crossings of filaments or pies-per-inch (PPI)) or fiber density along those portions of the body 150 to be higher where the enlarged portions 200 are disposed. When released or exposed to a fluid or heat, the enlarged portions 200 can move from the compressed position 210 to the expanded position 212, as shown in FIGS. 3F-3G. For example, in some embodiments, the enlarged portions 200 can be superelastic.


For example, when the enlarged portions. 200 are released (such as by uncurling, unrolling, or expanding from the collapsed position), the edges 172, 174 along the enlarged portions 200 can be spaced apart greater than the edges 172, 174 along the body 150. The edges 172, 174 can have a maximum width (for example, measured at a distance 220 in FIG. 3G) and a minimum width (for example, measured at a distance 222 in FIG. 3G). The maximum width 220 can be greater than the minimum width 222. In some embodiments, the maximum width 220 can be from about 1.1 to about 4 times as large, from about 1.5 to about 3.5 times as large, from about 2 to about 3 times as large, or from about 2.2 to about 2.8 times as large as the minimum width 222. In some embodiments, the, maximum width 220 may not exceed more than three or four times the minimum width 222.


Further, in some embodiments, as shown in FIG. 3G, the enlarged portion or wing 200 can comprise a width 224 that is approximately equal to the minimum width 222. Furthermore, and some embodiments, the width 224 of the enlarged portion or wing 200 can be between about 0.25 and about 2 times, about 0.5 to about 1.5 times, about 1 and about 1.25 times the minimum width 222.


In accordance with some embodiments, the enlarged portions 200 can be configured to have different widths, sizes (e.g., longitudinal lengths), or shapes along the length of the device 100. Thus, when released, the edges 172, 174 can define a generally irregular pattern. The maximum and minimum widths 220, 222 can be within the range, such as those discussed above.


Additionally, when released, the enlarged portions 200 can be configured to provide a fiber density or pattern that is substantially equivalent or identical to the fiber density or pattern of the body 150. However, the enlarged portions 200 can also be configured to provide a lower fiber density or different pattern than portions of the body 150 disposed adjacent to the respective enlarged portion or wing 200. In such embodiments, the enlarged portions 200 can be heat-set or otherwise pre-shaped in such a configuration.


As noted above, the enlarged portions 200 can be formed by stretching the body 150 to widen it at discrete locations along its length or by coupling a separate component to the body 150. In embodiments in which the enlarged portions 200 move between compressed and expanded positions, the enlarged portions 200 can be maintained in the, compressed position by exertion of a compressing force or by the use of a coating on the device 100, which can assist in maintaining the compressed position until the coating dissolves in the presence of fluid after release.


Referring now to FIG. 3H, in accordance with some embodiments, the body 150 can comprise first and second sections 240, 242 that can have different properties. For example, the body 150 can be configured such that a braid, weave, or knit pattern changes at least once or more or varies along the length of the body 150. In some embodiments, the body 150 can comprise a braided structure that comprises first and second sections 240, 242. The first and second sections 240, 242 can have different porosities, pic counts, filament pitch, filament size, or braid/weave/knit densities. Thus, the first and second sections 240, 242 can have different properties that can advantageously affect the function of the device 100 within the target area and during delivery to the target area.


For example, a higher pic count or braid density can tend to reduce or block flow through the device 100, while a lower pic count or braid density can permit flow or injection of embolic materials or coils through the device 100. Additionally, the pic count or braid density can also influence the frictional engagement with the target area wall and endothelialization when released, for example, at the neck of an aneurysm. Further, the pitch or alignment of the filaments can also affect longitudinal compressibility or pushability when urging the device 100 distally within the catheter toward the target area. For example, the fibers can be closely axially aligned with the longitudinal axis of the device 100, thus enhancing or increasing pushability of the device 100. Furthermore, a lower pic count can also tend to increase pushability of the device 100.


Referring now to FIG. 3I, the device 100 can also be configured such that at least one of the proximal and distal ends 250, 252 of the device 100 comprise an atraumatic feature or component. For example, the device 100 can be configured such that the proximal and/or distal ends 250, 252 comprises one or more points or corners (whether rounded or pointed) having a filament 260 extending therefrom. The filament 260 can allow the proximal and/or distal ends 250, 252 to gently and atraumatically contact the target area wall (such as an aneurysm wall). In some embodiments, the filament 260 can comprise a rounded or ball-shaped tip 262.



FIGS. 4-6B illustrate views of a device assembly 300 in which a device 100 is disposed within a catheter 302. As shown, the device 100 is in the collapsed configuration 120. In the illustrated embodiment, the device 100 comprises enlarged portions 200 that are folded or curled around the longitudinal axis of the device 100. Further, the device 100 also comprises atraumatic portions or filaments 260. Thus, the device 100 can be distally pushed out of the catheter 302 and into a target aneurysm whereat the device 100 can expand from the collapsed configuration 120 to the expanded configuration.


Additionally, in accordance with some embodiments, the device 100 can comprise a radiopaque marker at one or both of its ends, at locations along the length thereof, or along the entire length thereof. Such markers can be configured similar to the filament 260 and/or the rounded or ball-shaped tip 262 thereof. For example, the filament 260 and/or the rounded or ball-shape tip 262 thereof can be radiopaque.


The length of the device 100 can be from about 5 mm to about 250 mm. In some embodiments, the length can be from about 7 mm to about 180 mm. Further, the length can be from about 9 mm to about 100 mm. Furthermore, the length can be from about 10 mm to about 50 mm. The length of the device 100 can also be about 25 mm. As noted below, multiple devices having multiple lengths and/or configurations can also be used.


In some embodiments, the device can be configured such that a wall of the device 100 comprises a flow diverting pore size. A “flow diverting pore size” can refer to an average pore size of pores (in at least a section of a device) that is sufficiently small enough to interfere with or inhibit fluid exchange through the pores of that section.


A device 100 (e.g., at least a proximal section of the device) can have an active section or a flow diverting section with a flow diverting pore size when the pores of the section are sized to inhibit flow of blood through the sidewall into an aneurysm to a degree sufficient to lead to thrombosis and healing of the aneurysm when the tubular member is positioned in a blood vessel and adjacent to the aneurysm.


For example, a flow diverting pore size can be achieved when pores in the flow diverting or active section have an average pore size of less than about 500 microns when the device (e.g., stent) is in the expanded state. In some embodiments, the average pore size can be less than about 320 microns. Further, the average pore size can be from about 25 microns to about 350 microns. The average pore size can also be from about 40 microns to about 200 microns. Further, in some embodiments, the average pore size can be from about 60 microns to about 150 microns. Furthermore, the average pore size can be about 120 microns.


Average pore sizes that are about within such ranges can operate to divert fluid flow and induce thrombosis within the lumen or interior volume enclosed by the wall. The pores can have a pore size that is generally constant. The pores can have an average pore size that is measured using an inscribed circle diameter.


Additionally, in some embodiments, a device 100 can be provided with a porosity in the range of 10%-95% may be employed in the expanded braid to achieve these effects. In some embodiments, a porosity in the range of about 30% to about 90% may be employed to achieve these effects. Further, a porosity in the range of about 50% to about 85% may be employed to achieve these effects. Other various features can be incorporated into the device 100, such as those disclosed in copending International Application No. PCT/US13/33419, filed Mar. 22, 2013, the entirety of which is incorporated herein by reference.



FIGS. 5A-5B illustrate cross-sectional views of the device 100 and catheter 302 taken along section lines 5A-5A and 5B-5B of FIG. 4. Similar to the view illustrated in FIG. 2C, FIGS. 5A-5B illustrate a cross-sectional view of the device 100 in which the device is curved, curled, or rolled around or about a line 304 substantially parallel relative to the longitudinal axis 160 of the device 100.



FIGS. 6A-6B also illustrate other embodiments of the device in which the device is folded or compressed from a tubular or sheet configuration. For example, FIG. 6A illustrates that the device 100 can comprise a tubular shape that is flattened and curved, curled, or rolled around or about a line 304 substantially parallel relative to the longitudinal axis 160. Further, FIG. 6B illustrates that the device 100 can comprise a sheet that is folded at least once and curved, curled, or rolled around or about a line 304 substantially parallel relative to the longitudinal axis 160.


In accordance with some embodiments, the device 100 can exhibit improved or high pushability relative to comparable devices or structures by virtue of its collapsed configuration 120. The collapsed configuration 120 can improve pushability by reducing the amount of exposed material in contact with the catheter inner wall and/or by causing the collapse device to contact less than the full circumference of the catheter inner wall.


For example, because the device 100 is in a curved, curled, or rolled shape in the collapsed configuration 120, at least a portion of the device 100 will not come in contact with an interior surface or wall 310 of the catheter 302. In some embodiments, the interior wall 310 can be contacted along less than its full circumference. In its collapsed configuration 120, the device 100 will require much less pushing force than comparable structures that are otherwise simply radially collapsed or compressed from an expanded diameter to a compressed diameter (thereby either increasing the braid density or the axial length of the device in the collapsed state), as is typical with stents and other braided structures, such as braid balls.


For example, with reference to FIG. 5B, the device 100 can be rolled onto itself such that a cross-sectional inner portion of the device is radially within a cross-sectional outer portion of the device. The cross-sectional inner portion of the device can be, for purposes of this disclosure, considered as the rolled portion of the device that is radially overlapped by another portion of the device. As such, only the cross-sectional outer portion of the device will contact the inner wall 310 of the catheter 302.


Further, as illustrated in FIGS. 5A and 6A-6B, in some embodiments, the curled device 100 can extend along less than the entire circumference of the inner wall 310 of the catheter 302. As shown, in its folded or compressed, flattened cross-sectional configuration (which can be assumed in the expanded configuration, as illustrated in FIG. 2B), a cross-sectional width of the device 100 can be less than the circumference of the inner wall 310.


Accordingly, depending on the size of the catheter to be used, which can vary from about 3 Fr to about 8 Fr, the device 100 can be flattened or folded, and in some embodiments, rolled onto itself. When the device is not rolled onto itself (e.g., before insertion into the catheter), the width of the flattened cross-section can be between about 3 mm and about 7 mm, between about 4 mm and about 6 mm, or about 5 mm. Such dimensions can be used for single layer or multi-layer flattened cross-sections.


The device can be formed from a flat sheet. For example, if folded into two substantially equal sections before being rolled and inserted into a catheter, the flat sheet can have a width of between about 6 mm and about 14 mm, between about 8 mm and about 12 mm, or about 10 mm. Similar metrics can be followed when the device is formed using a folded sheet that has a trifold cross-section.


When the device is rolled onto itself, the cross-sectional diameter of the rolled, flattened material can be between about 1 mm and about 4 mm, between about 1.5 mm and about 3.5 mm, or between about 2 mm and about 3 mm. The cross-sectional diameter of the device, when rolled onto itself, can also tend to depend on the ability of the material to roll up in a delivery tube or catheter (e.g., its bending strength).


Thus, the collapsed configuration 120 of the device 100 can allow a greater amount of material or device to be advanced through the catheter 302 while minimizing the frictional resistance between the device 100 and catheter wall 310. As a result, the pushability of the device 100 can be advantageously improved.


In accordance with some embodiments, the various delivery methods and systems can also be provided. For example, one or more devices can be delivered using the systems disclosed herein in combination with a catheter. The device delivery system can comprise an elongate tube or catheter which slidably receives a core assembly configured to carry the device through the catheter. The catheter can have a proximal end and an opposing distal end which can be positioned at a treatment site within a patient, an internal lumen extending from the proximal end to the distal end, and an inner surface or wall facing the lumen. At the distal end, the catheter has a distal opening through which the core assembly and/or the device may be advanced beyond the distal end in order to expand, release, or deploy the device within the target area, such as a blood vessel or aneurysm. The proximal end may include a catheter hub. The catheter can define a generally longitudinal axis A-A extending between the proximal end and the distal end. When the delivery system is in use, the longitudinal axis need not be straight along some or any of its length.


The catheter can optionally comprise a microcatheter. For example, the catheter can optionally comprise any of the various lengths of the MARKSMAN™ catheter available from Covidien LP of Irvine, Calif. USA. The catheter can optionally comprise a microcatheter having an inner diameter of about 0.030 inches or less, and/or an outer diameter of 3 Fr or less near the distal end. Instead of or in addition to these specifications, the catheter can comprise a microcatheter which is configured to percutaneously access the internal carotid artery, or a location within the neurovasculature distal of the internal carotid artery, with its distal opening.


Information regarding additional embodiments of the catheter, and additional details and components that can optionally be used or implemented in the embodiments of the catheter described herein, can be found in U.S. Patent Application Publication No. US 2011/0238041 A1, published on Sep. 29, 2011, titled Variable Flexibility Catheter. The entirety of the aforementioned publication is hereby incorporated by reference herein and made a part of this specification.



FIGS. 7A-7F illustrate aspects of a delivery assembly 300 and occlusive device 100 that has been advanced to a target aneurysm 400. As illustrated in FIGS. 7A-7B, the device 100 can be advanced through a neck 402 of the aneurysm 400 toward the fundus 404 of the aneurysm 400. As the device 100 is advanced into the aneurysm 400, the device 100 can tend to uncurl, unroll, or expand from its collapsed configuration such that the opposing edges of the device move apart from each other and the released portion of the device 100 begins to assume a generally flat cross-sectional configuration.


As the device 100 continues to be advanced into the aneurysm 400, as shown in FIGS. 7C7D, the enlarged portions 200 of the device 100 and the body 150 of the device 100 can contact the inner wall or fundus 404 of the aneurysm 400. As the enlarged portions 200 and the body 150 contact the inner wall of the aneurysm 400, the device 100 can tend to frictionally contact or engage the inner wall of the aneurysm 400, thus reducing or eliminating slipping or sliding against the inner wall of the aneurysm 400, while maintaining the ability of the device 100 to conform and move freely within the aneurysm 400 during initial expansion and entry of the device 100 into the aneurysm 400. Accordingly, once a length of the device 100 is released into the aneurysm 400, which can be from about ¼ to about ¾, or from about ⅓ to about ⅔, or about ½ of the length of the device 100, the device 100 can tend to engage the inner wall of the aneurysm 400. Such engagement can allow the clinician to better predict the deployment characteristics or released position of the device 100 within the aneurysm 400. Additionally, such engagement can also enable the device 100 to be more securely retained within the aneurysm 400, thereby avoiding herniation of the device 100 from within the aneurysm 400.


Additionally, as illustrated in FIGS. 7E-7F, as the device 100 continues to advance into the aneurysm 400, the neck 402 will tend to be fully covered or blocked. For example, as the body 150 and additional enlarged portions 200 continue to be advanced into the aneurysm 400, the wings 200 and body 150 will tend to engage the inner wall of the aneurysm 400 extending over the neck. 402. Eventually, whether a single or multiple devices are inserted into the aneurysm 400, the volume of the aneurysm 400 can be substantially packed or filled such that circulation or fluid movement is slowed or stopped within the aneurysm 400 and in to the aneurysm 400 through the neck 402 is substantially slowed or stopped. FIG. 8 illustrates a view into the aneurysm 400 from below the aneurysm neck 402 after the device 100 or multiple devices are released into the aneurysm 400. The use of devices having the enlarged portions 200, although optional, can further improve the coverage of the neck 402 and engagement with the sidewall of the aneurysm 400.


Referring again to FIG. 8, substantial coverage of the aneurysm neck 402 using a device that has a textured surface, such as those mentioned above, including the braided or coated surfaces, can beneficially facilitate and invoke a healing response. Thus, superior neck coverage can allow endothelialization to more easily take place at the neck 402. Accordingly, some embodiments can be provided in which a single device is used to treat a wide neck aneurysm, in contrast to traditional treatments that require both a coil and the placement of a stent or other framing structure to prevent herniation of the coil from within the wide neck aneurysm.


In accordance with some embodiments, the delivery of one or more occlusive devices can be performed by delivering only a single occlusive device or multiple occlusive devices. For example, a first device can be released into the aneurysm that can function as the outermost layer of the group of devices deployed into the aneurysm. Subsequent devices can thereafter be inserted within the first framing device within the aneurysm. Such additional devices can comprise finishing coils or additional devices, such as those disclosed herein. The size and/or shape of the coils or devices subsequently released into the aneurysm can be progressively smaller or of a substantially identical or different size and/or shape.


According to one of the advantageous features of some embodiments disclosed herein, one or more devices can be delivered into the aneurysm without requiring the use of a framing structure to hold the devices within the aneurysm, which is required when using coils. Further, much better than coils, the devices disclosed herein can provide excellent neck coverage. Furthermore, much better than coils, the devices disclosed herein can reliably and predictably expand to preset shapes or configurations. Moreover, in contrast to stents or expandable braided structures, such as braided balls, the devices disclosed herein can pack or fill the volume of the target space, such as an aneurysm, much as coils are able to do. These and other such advantages disclosed herein, which traditionally are only achieved through multiple, separate components, can therefore be achieved using embodiments of the devices disclosed herein.


When delivering multiple devices into the aneurysm, the length of the devices, and in some embodiments, coils, can be between about 1 cm to about 10 cm. The order of delivery of such devices can be in order of progressive decrease in size. For example, the clinician can start with an 8 mm device, followed by one or more 7 mm devices, followed by one or more 6 mm devices, and so forth.


As noted above, the device 100 can comprise a nitinol or other material that tends to have a highly redictable shape when in the relaxed or released position. Thus, in contrast to coils, that will not tend to achieve a highly predictable shape (thereby being more random in their relaxed state), embodiments of the device 100 can advantageously allow a Clinician to provide a specifically shaped device to a target area of a specific shape or size. Such tailored therapy can improve the outcome for patients.


The apparatus and methods discussed herein are not limited to the deployment and use of a medical device within the vascular system but may include any number of further treatment applications. Other treatment sites may include areas or regions of the body including any hollow anatomical structures.


Although the detailed description contains many specifics, these should not be construed as limiting the scope of the subject technology but merely as illustrating different examples and aspects of the subject technology. It should be appreciated that the scope of the subject technology includes other embodiments not discussed in detail above. Various other modifications, changes and variations may be made in the arrangement, operation and details of the method and apparatus of the subject technology disclosed herein without departing from the scope of the present disclosure. Unless otherwise expressed, reference to an element in the singular is not intended to mean “one and only one” unless explicitly stated, but rather is meant to mean “one or more.” In addition, it is not necessary for a device or method to address every problem that is solvable (or possess every advantage that is achievable) by different embodiments of the disclosure in order to be encompassed within the scope of the disclosure. The use herein of “can” and derivatives thereof shall be understood in the sense of “possibly” or “optionally” as opposed to an affirmative capability.

Claims
  • 1. An occlusive device for occluding a target area, comprising: an elongate member formed of a single layer sheet of mesh material having opposing first and second side edges extending longitudinally along the member, the member having a length measured along its longitudinal axis and a width measured perpendicular to the length, wherein the width is less than the length, the member having: a collapsed configuration for delivery through a catheter to the target area, wherein, in the collapsed configuration the member is folded at least once and curled about a line substantially parallel to the longitudinal axis of the member, and the first and second side edges are positioned a first distance relative to one another; andan expanded configuration in which the member form a series of loops and the first and second side edges uncurl to be spaced apart from each other a second distance greater than the first distance.
  • 2. The device of claim 1, wherein the elongate member comprises a shape memory material.
  • 3. The device of claim 1, wherein the member comprises a plurality of interwoven filaments.
  • 4. The device of claim 3, wherein a spacing of the filaments varies along the length of the member.
  • 5. The device of claim 3, wherein the plurality of filaments are braided together.
  • 6. The device of claim 1, wherein the elongate member includes at least one slit.
  • 7. The device of claim 6, wherein the at least one slit extends along the longitudinal axis of the member.
  • 8. The device of claim 6, wherein the elongate member includes a plurality of slits extending along the longitudinal axis of the member and spaced apart in a substantially linear configuration.
  • 9. The device of claim 1, wherein the first and second side edges comprise a plurality of wing elements extending laterally therefrom.
  • 10. The device of claim 9, wherein the wing elements extend from opposing sides of the elongate member.
  • 11. The device of claim 10, wherein a pair of wing elements extend from opposing sides at a first longitudinal position along the member.
  • 12. The device of claim 10, wherein the wing elements comprise first and second sets of wing elements, the first set extending from a first side of the member and the second set extending from a second side of the member at different longitudinal positions than the first set.
US Referenced Citations (576)
Number Name Date Kind
3334629 Colm Aug 1967 A
3834394 Hunter et al. Sep 1974 A
4085757 Pevsner Apr 1978 A
4282875 Serbinenko et al. Aug 1981 A
4311146 Wonder Jan 1982 A
4327734 White, Jr. May 1982 A
4341218 U Jul 1982 A
4346712 Handa et al. Aug 1982 A
4364392 Strother et al. Dec 1982 A
4402319 Handa et al. Sep 1983 A
4441495 Hicswa Apr 1984 A
4494531 Gianturco Jan 1985 A
4517979 Pecenka May 1985 A
4545367 Tucci Oct 1985 A
4638803 Rand Jan 1987 A
4719924 Crittenden et al. Jan 1988 A
4735201 O'Reilly Apr 1988 A
4745919 Bundy et al. May 1988 A
4781177 Lebigot Nov 1988 A
4787899 Lazarus Nov 1988 A
4819637 Dormandy, Jr. et al. Apr 1989 A
4832055 Palestrant May 1989 A
4932419 de Toledo Jun 1990 A
4944746 Iwata et al. Jul 1990 A
4957501 Lahille et al. Sep 1990 A
4990155 Wilkoff Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5026377 Burton et al. Jun 1991 A
5035706 Giantureo et al. Jul 1991 A
5037427 Harada et al. Aug 1991 A
5062829 Pryor et al. Nov 1991 A
5104399 Lazarus Apr 1992 A
5108407 Geremia et al. Apr 1992 A
5109867 Twyford, Jr. May 1992 A
5122136 Guglielmi et al. Jun 1992 A
5133731 Butler et al. Jul 1992 A
5133732 Wiktor Jul 1992 A
5147370 McNamara et al. Sep 1992 A
5167624 Butler et al. Dec 1992 A
5181921 Makita et al. Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5211658 Clouse May 1993 A
5217484 Marks Jun 1993 A
5222970 Reeves Jun 1993 A
5224953 Morgentaler Jul 1993 A
5226911 Chee et al. Jul 1993 A
5234437 Sepetka Aug 1993 A
5250071 Palermo Oct 1993 A
5256146 Ensminger et al. Oct 1993 A
5261916 Engelson Nov 1993 A
5263964 Purdy Nov 1993 A
5304194 Chee et al. Apr 1994 A
5304195 Twyford, Jr. et al. Apr 1994 A
5312415 Palermo May 1994 A
5314472 Fontaine May 1994 A
5334210 Gianturco Aug 1994 A
5350397 Palermo et al. Sep 1994 A
5354295 Guglielmi et al. Oct 1994 A
5368592 Stern et al. Nov 1994 A
5382259 Phelps et al. Jan 1995 A
5382260 Dormandy, Jr. et al. Jan 1995 A
5382261 Palmaz Jan 1995 A
5397345 Lazarus Mar 1995 A
5417708 Hall et al. May 1995 A
5423829 Pham et al. Jun 1995 A
5423849 Engelson et al. Jun 1995 A
5443454 Tanabe et al. Aug 1995 A
5443478 Purdy Aug 1995 A
5456693 Conston et al. Oct 1995 A
5476472 Dormandy, Jr. et al. Dec 1995 A
5480382 Hammerslag et al. Jan 1996 A
5498227 Mawad Mar 1996 A
5507769 Marin et al. Apr 1996 A
5522822 Phelps et al. Jun 1996 A
5522836 Palermo Jun 1996 A
5527338 Purdy Jun 1996 A
5536274 Neuss Jul 1996 A
5540680 Guglielmi et al. Jul 1996 A
5549624 Mirigian et al. Aug 1996 A
5556426 Popadiuk et al. Sep 1996 A
5562698 Parker Oct 1996 A
5569245 Guglielmi et al. Oct 1996 A
5573520 Schwartz et al. Nov 1996 A
5578074 Mirigian Nov 1996 A
5582619 Ken Dec 1996 A
5601600 Ton Feb 1997 A
5624449 Pham et al. Apr 1997 A
5624461 Mariant Apr 1997 A
5626599 Bourne et al. May 1997 A
5634928 Fischell et al. Jun 1997 A
5639277 Mariant et al. Jun 1997 A
5643254 Scheldrup et al. Jul 1997 A
5645558 Horton Jul 1997 A
5645564 Northrup et al. Jul 1997 A
5649949 Wallace et al. Jul 1997 A
5658308 Snyder Aug 1997 A
5662700 Lazarus Sep 1997 A
5669905 Scheldrup et al. Sep 1997 A
5669931 Kupiecki et al. Sep 1997 A
5690666 Berenstein et al. Nov 1997 A
5690667 Gia Nov 1997 A
5690671 McGurk et al. Nov 1997 A
5693067 Purdy Dec 1997 A
5695517 Marin et al. Dec 1997 A
5700258 Mirigian et al. Dec 1997 A
5702361 Evans et al. Dec 1997 A
5718711 Berenstein et al. Feb 1998 A
5725534 Rasmussen Mar 1998 A
5725546 Samson Mar 1998 A
5725552 Kotula et al. Mar 1998 A
5733329 Wallace et al. Mar 1998 A
5743905 Eder et al. Apr 1998 A
5746734 Dormandy, Jr. et al. May 1998 A
5746769 Ton et al. May 1998 A
5749891 Ken et al. May 1998 A
5749894 Engelson May 1998 A
5749918 Hogendijk et al. May 1998 A
5759161 Ogawa et al. Jun 1998 A
5766219 Horton Jun 1998 A
5792157 Mische et al. Aug 1998 A
5797953 Tekulve Aug 1998 A
5800426 Taki et al. Sep 1998 A
5800453 Gia Sep 1998 A
5800454 Jacobsen et al. Sep 1998 A
5800455 Palermo et al. Sep 1998 A
5814062 Sepetka et al. Sep 1998 A
5830230 Berryman et al. Nov 1998 A
5833705 Ken et al. Nov 1998 A
5843118 Sepetka et al. Dec 1998 A
5846210 Ogawa et al. Dec 1998 A
5851206 Guglielmi et al. Dec 1998 A
5853418 Ken et al. Dec 1998 A
5855578 Guglielmi et al. Jan 1999 A
5891058 Taki et al. Apr 1999 A
5891128 Gia et al. Apr 1999 A
5891130 Palermo et al. Apr 1999 A
5891155 Irie Apr 1999 A
5891192 Murayama et al. Apr 1999 A
5895385 Guglielmi et al. Apr 1999 A
5895391 Farnholtz Apr 1999 A
5895410 Forber et al. Apr 1999 A
5895411 Irie Apr 1999 A
5911731 Pham et al. Jun 1999 A
5911737 Lee et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919187 Guglielmi et al. Jul 1999 A
5925037 Guglielmi et al. Jul 1999 A
5925059 Palermo et al. Jul 1999 A
5925060 Forber Jul 1999 A
5925062 Purdy Jul 1999 A
5928226 Guglielmi et al. Jul 1999 A
5935145 Villar et al. Aug 1999 A
5935148 Villar et al. Aug 1999 A
5941249 Maynard Aug 1999 A
5941888 Wallace et al. Aug 1999 A
5944714 Guglielmi et al. Aug 1999 A
5944733 Engelson Aug 1999 A
5947962 Guglielmi et al. Sep 1999 A
5947963 Guglielmi Sep 1999 A
5957948 Mariant Sep 1999 A
5964797 Ho Oct 1999 A
5972019 Engelson et al. Oct 1999 A
5976126 Guglielmi Nov 1999 A
5976131 Guglielmi et al. Nov 1999 A
5976152 Regan et al. Nov 1999 A
5976162 Doan et al. Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980550 Eder et al. Nov 1999 A
5980554 Lenker et al. Nov 1999 A
5984929 Bashiri et al. Nov 1999 A
5984944 Forber Nov 1999 A
5989242 Saadat et al. Nov 1999 A
6001092 Mirigian et al. Dec 1999 A
6004338 Ken et al. Dec 1999 A
6010498 Guglielmi Jan 2000 A
6013084 Ken et al. Jan 2000 A
6015424 Rosenbluth et al. Jan 2000 A
6017364 Lazarus Jan 2000 A
6017977 Evans et al. Jan 2000 A
6019757 Scheldrup Feb 2000 A
6019779 Thorud et al. Feb 2000 A
6022369 Jacobsen et al. Feb 2000 A
6024754 Engelson Feb 2000 A
6024765 Wallace et al. Feb 2000 A
6030413 Lazarus Feb 2000 A
6033423 Ken et al. Mar 2000 A
6039749 Marin et al. Mar 2000 A
6056770 Epstein et al. May 2000 A
6059779 Mills May 2000 A
6059815 Lee et al. May 2000 A
6063070 Eder May 2000 A
6063100 Diaz et al. May 2000 A
6063104 Villar et al. May 2000 A
6066133 Guglielmi et al. May 2000 A
6066149 Samson et al. May 2000 A
6066158 Engelson et al. May 2000 A
6068644 Lulo et al. May 2000 A
6074407 Levine et al. Jun 2000 A
6077260 Wheelock et al. Jun 2000 A
D427680 Mariant et al. Jul 2000 S
6083220 Guglielmi et al. Jul 2000 A
6086577 Ken et al. Jul 2000 A
6090125 Horton Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096546 Raskin Aug 2000 A
6102917 Maitland et al. Aug 2000 A
6102932 Kurz Aug 2000 A
6102933 Lee et al. Aug 2000 A
6113622 Hieshima Sep 2000 A
6117142 Goodson et al. Sep 2000 A
6117157 Tekulve Sep 2000 A
6123714 Gia et al. Sep 2000 A
6126672 Berryman et al. Oct 2000 A
6136015 Kurz et al. Oct 2000 A
6143007 Mariant et al. Nov 2000 A
6146373 Cragg et al. Nov 2000 A
6149664 Kurz Nov 2000 A
6149681 Houser et al. Nov 2000 A
6156061 Wallace et al. Dec 2000 A
6159165 Ferrera et al. Dec 2000 A
6159206 Ogawa Dec 2000 A
6165178 Bashiri et al. Dec 2000 A
6165193 Greene, Jr. et al. Dec 2000 A
6165198 McGurk et al. Dec 2000 A
6168570 Ferrera Jan 2001 B1
6168592 Kupiecki et al. Jan 2001 B1
6168610 Marin et al. Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6171326 Ferrera et al. Jan 2001 B1
6183491 Lulo Feb 2001 B1
6183495 Lenker et al. Feb 2001 B1
6187024 Boock et al. Feb 2001 B1
6187027 Mariant et al. Feb 2001 B1
6190373 Palermo et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6193728 Ken et al. Feb 2001 B1
RE37117 Palermo Mar 2001 E
6202261 Moore et al. Mar 2001 B1
6203547 Nguyen et al. Mar 2001 B1
6221066 Ferrera et al. Apr 2001 B1
6221086 Forber Apr 2001 B1
6224610 Ferrera May 2001 B1
6231573 Amor et al. May 2001 B1
6231586 Mariant May 2001 B1
6231590 Slaikeu et al. May 2001 B1
6231597 Deem et al. May 2001 B1
6238403 Greene, Jr. et al. May 2001 B1
6238415 Sepetka et al. May 2001 B1
6241691 Ferrera et al. Jun 2001 B1
6254592 Samson et al. Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6270495 Palermo Aug 2001 B1
6277125 Barry et al. Aug 2001 B1
6277126 Barry et al. Aug 2001 B1
6280457 Wallace et al. Aug 2001 B1
6281263 Evans et al. Aug 2001 B1
6287315 Wijeratne et al. Sep 2001 B1
6287318 Villar et al. Sep 2001 B1
6293960 Ken Sep 2001 B1
6296622 Kurz et al. Oct 2001 B1
6299619 Greene, Jr. et al. Oct 2001 B1
6299627 Eder et al. Oct 2001 B1
6306153 Kurz et al. Oct 2001 B1
6312405 Meyer et al. Nov 2001 B1
6312421 Boock Nov 2001 B1
6315709 Garibaldi et al. Nov 2001 B1
6319267 Kurz Nov 2001 B1
6322576 Wallace et al. Nov 2001 B1
6328750 Berry et al. Dec 2001 B1
6331184 Abrams Dec 2001 B1
6335384 Evans et al. Jan 2002 B1
6338736 Boosfeld et al. Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6346091 Jacobsen et al. Feb 2002 B1
6346117 Greenhalgh Feb 2002 B1
6348041 Klint Feb 2002 B1
6361547 Hieshima Mar 2002 B1
6364823 Garibaldi et al. Apr 2002 B1
6368338 Konya et al. Apr 2002 B1
6371972 Wallace et al. Apr 2002 B1
6375606 Garibaldi et al. Apr 2002 B1
6375628 Zadno-Azizi et al. Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6375669 Rosenbluth et al. Apr 2002 B1
6379329 Naglreiter et al. Apr 2002 B1
6379374 Hieshima et al. Apr 2002 B1
6383146 Klint May 2002 B1
6383174 Eder May 2002 B1
6383204 Ferrera et al. May 2002 B1
6383205 Samson et al. May 2002 B1
6409721 Wheelock et al. Jun 2002 B1
6416535 Lazarus Jul 2002 B1
6416541 Denardo Jul 2002 B2
6423085 Murayama et al. Jul 2002 B1
6425893 Guglielmi Jul 2002 B1
6425914 Wallace et al. Jul 2002 B1
6428557 Hilaire Aug 2002 B1
6428558 Jones et al. Aug 2002 B1
6454780 Wallace Sep 2002 B1
6458119 Berenstein et al. Oct 2002 B1
6458127 Truckai Oct 2002 B1
6458137 Klint Oct 2002 B1
6464699 Swanson Oct 2002 B1
6468266 Bashiri et al. Oct 2002 B1
6475169 Ferrera Nov 2002 B2
6475227 Burke et al. Nov 2002 B2
6478773 Gandhi et al. Nov 2002 B1
6485524 Strecker Nov 2002 B2
6494884 Gifford, III et al. Dec 2002 B2
6500149 Gandhi et al. Dec 2002 B2
6500190 Greene, Jr. et al. Dec 2002 B2
6506204 Mazzocchi Jan 2003 B2
6511468 Cragg et al. Jan 2003 B1
6514264 Naglreiter Feb 2003 B1
6530934 Jacobsen et al. Mar 2003 B1
6533801 Wallace et al. Mar 2003 B2
6537293 Berryman et al. Mar 2003 B1
6540657 Cross, III et al. Apr 2003 B2
6544163 Wallace et al. Apr 2003 B2
6544225 Lulo et al. Apr 2003 B1
6544268 Lazarus Apr 2003 B1
6544275 Teoh Apr 2003 B1
6547804 Porter et al. Apr 2003 B2
6551305 Ferrera et al. Apr 2003 B2
6551340 Konya et al. Apr 2003 B1
6554849 Jones et al. Apr 2003 B1
6558367 Cragg et al. May 2003 B1
6569179 Teoh et al. May 2003 B2
6572628 Dominguez et al. Jun 2003 B2
6575994 Marin et al. Jun 2003 B1
6585748 Jeffree Jul 2003 B1
6585754 Wallace et al. Jul 2003 B2
6589227 Klint Jul 2003 B2
6589230 Gia et al. Jul 2003 B2
6589236 Wheelock et al. Jul 2003 B2
6589265 Palmer et al. Jul 2003 B1
6592605 Lenker et al. Jul 2003 B2
6602261 Greene, Jr. et al. Aug 2003 B2
6602269 Wallace et al. Aug 2003 B2
6603994 Wallace et al. Aug 2003 B2
6605101 Schaefer et al. Aug 2003 B1
6607538 Ferrera et al. Aug 2003 B1
6607539 Hayashi et al. Aug 2003 B1
6610085 Lazarus Aug 2003 B1
6613074 Mitelberg et al. Sep 2003 B1
6616617 Ferrera et al. Sep 2003 B1
6620152 Guglielmi Sep 2003 B2
6623493 Wallace et al. Sep 2003 B2
6632241 Hancock et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635069 Teoh et al. Oct 2003 B1
6638291 Ferrera et al. Oct 2003 B1
6638293 Makower et al. Oct 2003 B1
6656173 Palermo Dec 2003 B1
6656201 Ferrera et al. Dec 2003 B2
6656218 Denardo et al. Dec 2003 B1
6656351 Boyle Dec 2003 B2
6660020 Wallace et al. Dec 2003 B2
6663607 Slaikeu et al. Dec 2003 B2
6679903 Kurz Jan 2004 B2
6685653 Ehr et al. Feb 2004 B2
6685696 Fleischhacker et al. Feb 2004 B2
6689141 Ferrera et al. Feb 2004 B2
6692510 West Feb 2004 B2
6702844 Lazarus Mar 2004 B1
6716238 Elliott Apr 2004 B2
6723112 Ho et al. Apr 2004 B2
6743236 Barry et al. Jun 2004 B2
6743251 Eder Jun 2004 B1
6767358 Leonhardt et al. Jul 2004 B2
6811561 Diaz et al. Nov 2004 B2
6814748 Baker et al. Nov 2004 B1
6835185 Ramzipoor et al. Dec 2004 B2
6849081 Sepetka et al. Feb 2005 B2
6852116 Leonhardt et al. Feb 2005 B2
6853418 Suzuki et al. Feb 2005 B2
6855153 Saadat Feb 2005 B2
6855155 Denardo et al. Feb 2005 B2
6860893 Wallace et al. Mar 2005 B2
6860901 Baker et al. Mar 2005 B1
6872218 Kurz et al. Mar 2005 B2
6878163 Denardo et al. Apr 2005 B2
6905503 Gifford, III et al. Jun 2005 B2
6913618 Denardo et al. Jul 2005 B2
6929654 Teoh et al. Aug 2005 B2
6945956 Waldhauser et al. Sep 2005 B2
6958061 Truckai et al. Oct 2005 B2
6958068 Hieshima Oct 2005 B2
6964657 Cragg et al. Nov 2005 B2
6966892 Gandhi et al. Nov 2005 B2
6984240 Ken et al. Jan 2006 B1
6994689 Zadno-Azizi et al. Feb 2006 B1
6994711 Hieshima et al. Feb 2006 B2
7014645 Greene, Jr. et al. Mar 2006 B2
7029486 Schaefer et al. Apr 2006 B2
7029487 Greene, Jr. et al. Apr 2006 B2
7033374 Schaefer et al. Apr 2006 B2
7058456 Pierce Jun 2006 B2
7060083 Gerberding Jun 2006 B2
7070607 Murayama et al. Jul 2006 B2
7147618 Kurz Dec 2006 B2
7169161 Bonnette et al. Jan 2007 B2
7182774 Barry et al. Feb 2007 B2
7198613 Gandhi et al. Apr 2007 B2
7238194 Monstadt et al. Jul 2007 B2
7300458 Henkes et al. Nov 2007 B2
7316701 Ferrera et al. Jan 2008 B2
7323000 Monstdt et al. Jan 2008 B2
7331973 Gesswein et al. Feb 2008 B2
7344558 Lorenzo et al. Mar 2008 B2
7410482 Murphy et al. Aug 2008 B2
7473266 Glaser Jan 2009 B2
7485122 Teoh Feb 2009 B2
7485317 Murayama et al. Feb 2009 B1
7524322 Monstdt et al. Apr 2009 B2
7575582 Gandhi et al. Aug 2009 B2
7578826 Gandhi et al. Aug 2009 B2
RE41029 Guglielmi et al. Dec 2009 E
7691124 Balgobin Apr 2010 B2
7708755 Davis, III et al. May 2010 B2
7722636 Farnan May 2010 B2
7722637 Barry et al. May 2010 B2
7766933 Davis, III et al. Aug 2010 B2
7811305 Balgobin et al. Oct 2010 B2
7841994 Skujins et al. Nov 2010 B2
7879064 Monstadt et al. Feb 2011 B2
7883526 Jones et al. Feb 2011 B2
7896899 Patterson et al. Mar 2011 B2
7901444 Slazas Mar 2011 B2
7901704 Richard Mar 2011 B2
7918872 Mitelberg et al. Apr 2011 B2
7938845 Aganon et al. May 2011 B2
7955272 Rooney et al. Jun 2011 B2
8002789 Ramzipoor et al. Aug 2011 B2
8007509 Buiser et al. Aug 2011 B2
8372110 Monstadt et al. Feb 2013 B2
8690907 Janardhan Apr 2014 B1
20020010481 Jayaraman Jan 2002 A1
20020019647 Wallace et al. Feb 2002 A1
20020052613 Ferrera et al. May 2002 A1
20020065529 Laurent et al. May 2002 A1
20020072712 Nool et al. Jun 2002 A1
20020072791 Eder et al. Jun 2002 A1
20020082620 Lee Jun 2002 A1
20020087184 Eder et al. Jul 2002 A1
20020120297 Shadduck Aug 2002 A1
20020128671 Wallace et al. Sep 2002 A1
20020138095 Mazzocchi et al. Sep 2002 A1
20020143349 Gifford et al. Oct 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20030014073 Bashiri et al. Jan 2003 A1
20030040733 Cragg et al. Feb 2003 A1
20030045901 Opolski Mar 2003 A1
20030083676 Wallace May 2003 A1
20030130689 Wallace et al. Jul 2003 A1
20030169473 Cotter et al. Sep 2003 A1
20030176857 Lee Sep 2003 A1
20030181927 Wallace Sep 2003 A1
20030216772 Konya et al. Nov 2003 A1
20030225365 Greff et al. Dec 2003 A1
20040002731 Aganon et al. Jan 2004 A1
20040002732 Teoh et al. Jan 2004 A1
20040002733 Teoh Jan 2004 A1
20040006354 Schaefer et al. Jan 2004 A1
20040006362 Schaefer et al. Jan 2004 A1
20040006363 Schaefer Jan 2004 A1
20040024394 Wallace et al. Feb 2004 A1
20040034363 Wilson et al. Feb 2004 A1
20040034378 Monstadt et al. Feb 2004 A1
20040045554 Schaefer et al. Mar 2004 A1
20040078050 Monstadt et al. Apr 2004 A1
20040082879 Klint Apr 2004 A1
20040106946 Ferrera et al. Jun 2004 A1
20040181256 Glaser Sep 2004 A1
20040193178 Nikolchev Sep 2004 A1
20040193206 Gerberding et al. Sep 2004 A1
20040220563 Eder Nov 2004 A1
20040220585 Nikolchev Nov 2004 A1
20040225279 Raymond Nov 2004 A1
20040236344 Monstadt et al. Nov 2004 A1
20040260384 Allen Dec 2004 A1
20050021023 Guglielmi et al. Jan 2005 A1
20050021074 Elliott Jan 2005 A1
20050079196 Henkes et al. Apr 2005 A1
20050171572 Martinez Aug 2005 A1
20050177185 Becker et al. Aug 2005 A1
20050187564 Jayaraman Aug 2005 A1
20050274384 Tran Dec 2005 A1
20050277978 Greenhalgh Dec 2005 A1
20060025801 Lulo et al. Feb 2006 A1
20060025802 Sowers Feb 2006 A1
20060030933 DeLegge Feb 2006 A1
20060036281 Patterson et al. Feb 2006 A1
20060079926 Desai et al. Apr 2006 A1
20060106417 Tessmer et al. May 2006 A1
20060116711 Elliott et al. Jun 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116714 Sepetka et al. Jun 2006 A1
20060200190 Lorenzo et al. Sep 2006 A1
20060253148 Leone et al. Nov 2006 A1
20060271097 Ramzipoor et al. Nov 2006 A1
20060276824 Mitelberg et al. Dec 2006 A1
20070055302 Henry et al. Mar 2007 A1
20070083226 Buiser et al. Apr 2007 A1
20070142893 Buiser et al. Jun 2007 A1
20070150045 Ferrera Jun 2007 A1
20070173757 Levine et al. Jul 2007 A1
20070185524 Diaz et al. Aug 2007 A1
20070225738 Pal Sep 2007 A1
20070239193 Simon et al. Oct 2007 A1
20070239199 Jayaraman Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070282425 Kleine et al. Dec 2007 A1
20070299461 Elliott Dec 2007 A1
20080045922 Cragg et al. Feb 2008 A1
20080046092 Davis et al. Feb 2008 A1
20080046093 Davis et al. Feb 2008 A1
20080051803 Monjtadt et al. Feb 2008 A1
20080097401 Trapp et al. Apr 2008 A1
20080097462 Mitelberg et al. Apr 2008 A1
20080097508 Jones Apr 2008 A1
20080103585 Monstadt et al. May 2008 A1
20080125798 Osborne May 2008 A1
20080125855 Henkes et al. May 2008 A1
20080228215 Strauss et al. Sep 2008 A1
20080228216 Strauss et al. Sep 2008 A1
20080300616 Que et al. Dec 2008 A1
20080306504 Win et al. Dec 2008 A1
20080319532 Monstadt et al. Dec 2008 A1
20090025820 Adams Jan 2009 A1
20090048631 Bhatnagar et al. Feb 2009 A1
20090069836 Labdag et al. Mar 2009 A1
20090149864 Porter Jun 2009 A1
20090182268 Thielen et al. Jul 2009 A1
20090254111 Monstadt et al. Oct 2009 A1
20090254169 Spenser et al. Oct 2009 A1
20090270877 Johnson et al. Oct 2009 A1
20090312748 Johnson et al. Dec 2009 A1
20100004673 Denison et al. Jan 2010 A1
20100004675 Wilson et al. Jan 2010 A1
20100023105 Levy et al. Jan 2010 A1
20100030200 Strauss et al. Feb 2010 A1
20100030319 Weber Feb 2010 A1
20100049165 Sutherland et al. Feb 2010 A1
20100069948 Veznedaroglu Mar 2010 A1
20100076479 Monstadt Mar 2010 A1
20100174269 Tompkins et al. Jul 2010 A1
20100324538 Van Orden Dec 2010 A1
20110022003 Tekulve Jan 2011 A1
20110082493 Samson et al. Apr 2011 A1
20110098814 Monstadt et al. Apr 2011 A1
20110118777 Patterson et al. May 2011 A1
20110172700 Bose et al. Jul 2011 A1
20110184454 Barry et al. Jul 2011 A1
20110213405 Porter et al. Sep 2011 A1
20110213406 Aganon et al. Sep 2011 A1
20110245861 Chen et al. Oct 2011 A1
20110313447 Strauss et al. Dec 2011 A1
20120239074 Aboytes Sep 2012 A1
20130066357 Aboytes Mar 2013 A1
20130116722 Aboytes May 2013 A1
20130190801 Divino et al. Jul 2013 A1
20130253572 Molaei Sep 2013 A1
20140277099 Wallace Sep 2014 A1
20150080937 Davidson Mar 2015 A1
20150150563 Marchand Jun 2015 A1
20150313599 Johnson Nov 2015 A1
20160022270 Watson Jan 2016 A1
20160022445 Ruvalcaba Jan 2016 A1
20160206323 Hebert Jul 2016 A1
20160249935 Hewitt Sep 2016 A1
20160262766 Aboytes Sep 2016 A1
Foreign Referenced Citations (161)
Number Date Country
2144725 May 1994 CA
2265062 Sep 1999 CA
1668250 Sep 2005 CN
4445715 Jun 1996 DE
69627243 Jan 1997 DE
19547617 Sep 1997 DE
19607451 Sep 1997 DE
19610333 Sep 1997 DE
19647280 May 2001 DE
19952387 May 2001 DE
10010840 Sep 2001 DE
10118017 Oct 2002 DE
10155191 May 2003 DE
707830 Apr 1996 EP
711532 May 1996 EP
717969 Jun 1996 EP
720838 Jul 1996 EP
765636 Apr 1997 EP
792623 Sep 1997 EP
820726 Jan 1998 EP
829236 Mar 1998 EP
830873 Mar 1998 EP
853955 Jul 1998 EP
865773 Sep 1998 EP
882428 Sep 1998 EP
904737 Mar 1999 EP
914807 May 1999 EP
941700 Sep 1999 EP
941701 Sep 1999 EP
992220 Apr 2000 EP
1005837 Jun 2000 EP
1120088 Aug 2001 EP
1125553 Aug 2001 EP
1129666 Sep 2001 EP
1142535 Oct 2001 EP
1169969 Jan 2002 EP
1188413 Mar 2002 EP
1188414 Mar 2002 EP
1295563 Mar 2003 EP
1312312 May 2003 EP
1316293 Jun 2003 EP
1358850 Nov 2003 EP
1374801 Jan 2004 EP
1669032 Jun 2006 EP
1738698 Jan 2007 EP
832607 Apr 2008 EP
2260800 Dec 2010 EP
2292147 Mar 2011 EP
6-246004 Sep 1994 JP
7-155331 Jun 1995 JP
7-265431 Oct 1995 JP
7-284534 Oct 1995 JP
9-168541 Jun 1997 JP
10-201766 Aug 1998 JP
11-47138 Feb 1999 JP
11-76249 Mar 1999 JP
2001-513389 Sep 2001 JP
2002-523172 Jul 2002 JP
2003265620 Sep 2003 JP
2004-500929 Jan 2004 JP
2006-051349 Feb 2006 JP
2008-525113 Jul 2008 JP
2013537069 Sep 2013 JP
2010107255 Oct 2010 KR
1014547 Feb 2011 KR
WO-8803817 Jun 1988 WO
WO-8906984 Aug 1989 WO
WO-9012616 Nov 1990 WO
WO-9113592 Sep 1991 WO
WO-9214408 Sep 1992 WO
WO-9221400 Dec 1992 WO
WO-9311719 Jun 1993 WO
WO-9316650 Sep 1993 WO
WO-9406502 Mar 1994 WO
WO-9406503 Mar 1994 WO
WO-9410936 May 1994 WO
WO-9411051 May 1994 WO
WO-9426175 Nov 1994 WO
WO-9512367 May 1995 WO
WO-9618343 Jun 1996 WO
WO-9632153 Oct 1996 WO
WO-9639950 Dec 1996 WO
WO-9727888 Aug 1997 WO
WO-9742881 Nov 1997 WO
WO-9809570 Mar 1998 WO
WO-9817183 Apr 1998 WO
WO-9833452 Aug 1998 WO
WO-9834546 Aug 1998 WO
WO-9839048 Sep 1998 WO
WO-9858590 Dec 1998 WO
WO-9902094 Jan 1999 WO
WO-9905977 Feb 1999 WO
WO-9907292 Feb 1999 WO
WO-9909893 Mar 1999 WO
WO-9932037 Jul 1999 WO
WO-9942038 Aug 1999 WO
WO-9944538 Sep 1999 WO
WO-9949812 Oct 1999 WO
WO-9956636 Nov 1999 WO
WO-0012016 Mar 2000 WO
WO-0013593 Mar 2000 WO
WO-0025680 May 2000 WO
WO-0044306 Aug 2000 WO
WO-0072781 Dec 2000 WO
WO-0132085 May 2001 WO
WO-0145571 Jun 2001 WO
WO-0156500 Aug 2001 WO
WO-0158365 Aug 2001 WO
WO-0158382 Aug 2001 WO
WO-0187184 Nov 2001 WO
WO-0193937 Dec 2001 WO
WO-0202018 Jan 2002 WO
WO-0213705 Feb 2002 WO
WO-0213706 Feb 2002 WO
WO-0232496 Apr 2002 WO
WO-0239911 May 2002 WO
WO-0241753 May 2002 WO
WO-0245596 Jun 2002 WO
WO-02054943 Jul 2002 WO
WO-02054980 Jul 2002 WO
WO-02072168 Sep 2002 WO
WO-02087449 Nov 2002 WO
WO-02087651 Nov 2002 WO
WO-02089676 Nov 2002 WO
WO-02096273 Dec 2002 WO
WO-02096301 Dec 2002 WO
WO-03001970 Jan 2003 WO
WO-03007823 Jan 2003 WO
WO-03017852 Mar 2003 WO
WO-03034927 May 2003 WO
WO-03039624 May 2003 WO
WO-03041615 May 2003 WO
WO-03053257 Jul 2003 WO
WO-03053281 Jul 2003 WO
WO-03073914 Sep 2003 WO
WO-03077776 Sep 2003 WO
WO-03077984 Sep 2003 WO
WO-03082128 Oct 2003 WO
WO-03086240 Oct 2003 WO
WO-03092547 Nov 2003 WO
WO-03099370 Dec 2003 WO
WO-2004008974 Jan 2004 WO
WO-2004010878 Feb 2004 WO
WO-2004014239 Feb 2004 WO
WO-2004069059 Aug 2004 WO
WO-2004073529 Sep 2004 WO
WO-2005065556 Jul 2005 WO
WO-2006058042 Jun 2006 WO
WO-2006069123 Jun 2006 WO
WO-2007121405 Oct 2007 WO
WO-2008112435 Sep 2008 WO
WO-2008112436 Sep 2008 WO
WO-2008127328 Oct 2008 WO
WO-2010092174 Aug 2010 WO
WO-2010117883 Oct 2010 WO
WO-2010123821 Oct 2010 WO
WO-2010134914 Nov 2010 WO
WO-2011030820 Mar 2011 WO
2012034135 Mar 2012 WO
WO-2012034135 Mar 2012 WO
WO-2012161953 Nov 2012 WO
Non-Patent Literature Citations (2)
Entry
U.S. Appl. No. 13/764,028, filed Feb. 11, 2013, Not Yet Published.
U.S. Appl. No. 13/764,028, filed Feb. 11, 2013.
Related Publications (1)
Number Date Country
20150297240 A1 Oct 2015 US